Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants
← catalyst calendarSponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
224actual
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-30 | actual | When the study began enrolling |
| Primary completion | 2025-04-07 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-09 | actual | The whole study's end, after follow-up |
| First posted | 2024-06-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: Aspirin
- Drug: REGN9933
- Drug: REGN7508
- Drug: Rivaroxaban
Primary outcome
what the primary-completion date above is the date OFChange in fecal hemoglobin content (FHC)
measured Baseline and up to day 22
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed